[1] Orforglipron: A Milestone in Oral GLP-1 RA Development Eli Lilly also presented positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone
Taking into account the expected BMD loss in postmenopausal women, the improvement in spine and femoral neck BMD was approximately 7% relative to predicted decline, representing a pronounced, clinically relevant effect
Biologically, youre having parallel processes in different organs that probably have some underlying pathophysiology in common
However, tracking is delayed, media-logo claims are unverifiable, and Trustpilot sentiment is mixed
Available from: [2] Dutta P, Kumar Y, Babu AT, Giri Ravindran S, Salam A, Rai B, et al